The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 June 2026•

2 min read

Galectin Therapeutics Surges 11% on FDA Alignment for MASH Cirrhosis Drug

Key Facts

1Galectin Therapeutics stock rose 11% following FDA alignment on key elements of the Phase III program for belapectin.

In a move reflecting significant regulatory progress in the biotech sector, Galectin Therapeutics (GALT) shares jumped 11% following alignment with the U.S. Food and Drug Administration (FDA) on the Phase III program for its drug, belapectin. According to reports, the agreement covers the clinical trial design and the regulatory path toward full approval for treating MASH-related cirrhosis. This alignment clarifies the requirements for the pivotal NAVIGATE study, effectively reducing regulatory uncertainty and providing a clearer roadmap to market.

This development is particularly critical as it follows a period of volatility; the NAVIGATE trial previously missed its primary endpoint in late 2024, making this fresh FDA consensus a vital milestone for the company's recovery. In the broader MASH treatment landscape, peer companies show varied performance, with Madrigal Pharmaceuticals (MDGL) priced at $2.83 (close June 23, 2026) and Akero Therapeutics (AKRO) at $54.65 per market data. Galectin is now actively exploring strategic and financial partnerships to fund the continued commercialization of its lead asset.

GALT shares ended the session at $3.12 (close June 23, 2026) on significantly elevated volume of approximately 4 million shares. Investors should look ahead to the third quarter of 2026, when the company intends to file the final Phase III protocol with the FDA. Additionally, broader market sentiment may be influenced by upcoming economic catalysts, including the U.S. Initial Jobless Claims report scheduled for June 18, 2026, which often impacts small-cap biotech valuations.